Retatrutide Cost Tracker: Price Updates
Cost is a critical factor for patients considering retatrutide. While official pricing has not been announced (the drug is not yet FDA-approved), we can make informed estimates based on Eli Lilly's pricing for tirzepatide and the broader GLP-1 market. This tracker will be updated as pricing information becomes available (Jastreboff et al., NEJM 2023).
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. All pricing information is estimated and subject to change.
Estimated Brand-Name Cost
| Access Method | Estimated Monthly Cost | Notes |
|---|---|---|
| Brand-name (no insurance) | $1,000-1,500+ | Based on tirzepatide pricing |
| Brand-name (with insurance) | $25-300 (copay) | Varies by plan; many plans exclude weight loss |
| Manufacturer savings card | Potentially $25-500 | Lilly likely to offer; eligibility varies |
| Compounded version | TBD | Depends on compounding pharmacy availability |
Context: Current GLP-1 Pricing
| Medication | List Price/Month | Compounded Price |
|---|---|---|
| Wegovy (semaglutide) | ~$1,350 | $125/mo (at Trimi) |
| Zepbound (tirzepatide) | ~$1,060 | $125/mo (at Trimi) |
| Ozempic (semaglutide) | ~$935 | $125/mo (at Trimi) |
| Saxenda (liraglutide) | ~$1,400 | N/A |
Insurance Coverage Outlook
Insurance coverage for retatrutide will likely follow the pattern established by tirzepatide: strong coverage when prescribed for type 2 diabetes, limited and variable coverage for obesity/weight loss indication, increasing employer plan coverage as obesity treatment gains acceptance, and Medicare coverage uncertain (currently does not cover anti-obesity medications, but legislation is pending).
Compounding Pharmacy Access
Compounded versions of GLP-1 medications have become a major access pathway, particularly for semaglutide and tirzepatide. Whether compounded retatrutide will be available depends on patent and exclusivity status, FDA enforcement decisions regarding compounding, compounding pharmacy capabilities, and active pharmaceutical ingredient (API) availability.
Cost-Effectiveness Perspective
When evaluating retatrutide cost, consider the broader economic picture: obesity treatment costs ($1,800-7,000+ annually for medications alone) compared to obesity-related health costs ($15,000-30,000+ annually including diabetes medications, cardiovascular events, joint replacements, sleep apnea treatment, and lost productivity). The medication cost is often far less than the cost of not treating obesity.
Affordable GLP-1 Treatment Available Now
While retatrutide pricing develops, effective GLP-1 treatment is available at accessible prices. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month, a fraction of brand-name costs. Learn how Trimi works.
Frequently Asked Questions
How much will retatrutide cost?
Official pricing has not been announced. Based on tirzepatide pricing and market dynamics, brand-name retatrutide is likely to cost $1,000-1,500+ per month without insurance.
Will my insurance cover retatrutide?
Coverage will depend on your specific plan and the approved indication. Coverage for diabetes is more likely than for weight loss. Check with your insurer after FDA approval.
Will there be a generic retatrutide?
Not for many years. Patent protection and regulatory exclusivity typically protect brand-name biologics for 12+ years after approval.
What is the cheapest way to get GLP-1 treatment now?
Compounded semaglutide through providers like Trimi ($99/month) is currently the most affordable option for GLP-1 therapy with medical oversight.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).